465 related articles for article (PubMed ID: 28796920)
1. Recommendations for the management of comorbidity in hidradenitis suppurativa.
Dauden E; Lazaro P; Aguilar MD; Blasco AJ; Suarez C; Marin I; Queiro R; Bassas-Vila J; Martorell A; García-Campayo J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):129-144. PubMed ID: 28796920
[TBL] [Abstract][Full Text] [Related]
2. Position statement for the management of comorbidities in psoriasis.
Dauden E; Blasco AJ; Bonanad C; Botella R; Carrascosa JM; González-Parra E; Jodar E; Joven B; Lázaro P; Olveira A; Quintero J; Rivera R
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2058-2073. PubMed ID: 29992631
[TBL] [Abstract][Full Text] [Related]
3. [Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis-associated Comorbidities].
Daudén E; Castañeda S; Suárez C; García-Campayo J; Blasco AJ; Aguilar MD; Ferrándiz C; Puig L; Sánchez-Carazo JL;
Actas Dermosifiliogr; 2012 Jan; 103 Suppl 1():1-64. PubMed ID: 22364603
[TBL] [Abstract][Full Text] [Related]
4. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.
Shlyankevich J; Chen AJ; Kim GE; Kimball AB
J Am Acad Dermatol; 2014 Dec; 71(6):1144-50. PubMed ID: 25440440
[TBL] [Abstract][Full Text] [Related]
5. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
Garg A; Malviya N; Strunk A; Wright S; Alavi A; Alhusayen R; Alikhan A; Daveluy SD; Delorme I; Goldfarb N; Gulliver W; Hamzavi I; Jaleel T; Kimball AB; Kirby JS; Kirchhof MG; Lester J; Lev-Tov H; Lowes MA; Micheletti R; Orenstein LA; Piguet V; Sayed C; Tan J; Naik HB
J Am Acad Dermatol; 2022 May; 86(5):1092-1101. PubMed ID: 33493574
[TBL] [Abstract][Full Text] [Related]
6. Systemic associations of hidradenitis suppurativa.
Kohorst JJ; Kimball AB; Davis MD
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S27-35. PubMed ID: 26470611
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa.
Miller IM; McAndrew RJ; Hamzavi I
Dermatol Clin; 2016 Jan; 34(1):7-16. PubMed ID: 26617352
[TBL] [Abstract][Full Text] [Related]
8. Endocrinologic Aspects of Hidradenitis Suppurativa.
Karagiannidis I; Nikolakis G; Zouboulis CC
Dermatol Clin; 2016 Jan; 34(1):45-9. PubMed ID: 26617357
[TBL] [Abstract][Full Text] [Related]
9. Association of metabolic syndrome and hidradenitis suppurativa.
Miller IM; Ellervik C; Vinding GR; Zarchi K; Ibler KS; Knudsen KM; Jemec GB
JAMA Dermatol; 2014 Dec; 150(12):1273-80. PubMed ID: 25229996
[TBL] [Abstract][Full Text] [Related]
10. Which hidradenitis suppurativa comorbidities should I take into account?
Tzellos T; Zouboulis CC
Exp Dermatol; 2022 Sep; 31 Suppl 1():29-32. PubMed ID: 35737874
[TBL] [Abstract][Full Text] [Related]
11. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.
Zouboulis CC; Bechara FG; Dickinson-Blok JL; Gulliver W; Horváth B; Hughes R; Kimball AB; Kirby B; Martorell A; Podda M; Prens EP; Ring HC; Tzellos T; van der Zee HH; van Straalen KR; Vossen ARJV; Jemec GBE
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):19-31. PubMed ID: 30176066
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of cardiovascular comorbidities in hidradenitis suppurativa: A nationwide, population-based, cohort study in Taiwan.
Hung CT; Chiang CP; Chung CH; Tsao CH; Chien WC; Wang WM
J Dermatol; 2019 Oct; 46(10):867-873. PubMed ID: 31389066
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa.
Gold DA; Reeder VJ; Mahan MG; Hamzavi IH
J Am Acad Dermatol; 2014 Apr; 70(4):699-703. PubMed ID: 24433875
[TBL] [Abstract][Full Text] [Related]
14. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis.
Scheinfeld N
Dermatol Online J; 2013 Jun; 19(6):18558. PubMed ID: 24011308
[TBL] [Abstract][Full Text] [Related]
15. The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014.
Ramos-Rodriguez AJ; Timerman D; Khan A; Bonomo L; Hunjan MK; Lemor A
Int J Dermatol; 2018 May; 57(5):547-552. PubMed ID: 29431201
[TBL] [Abstract][Full Text] [Related]
16. Swiss Practice Recommendations for the Management of Hidradenitis Suppurativa/Acne Inversa.
Hunger RE; Laffitte E; Läuchli S; Mainetti C; Mühlstädt M; Schiller P; Lapointe AK; Meschberger P; Navarini AA
Dermatology; 2017; 233(2-3):113-119. PubMed ID: 28683447
[TBL] [Abstract][Full Text] [Related]
17. Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice.
Prens EP; Lugo-Somolinos AM; Paller AS; Kerdel F; Duan Y; Teixeira HD; Longcore M; Kimball AB
Am J Clin Dermatol; 2020 Aug; 21(4):579-590. PubMed ID: 32077014
[TBL] [Abstract][Full Text] [Related]
18. Risk of cardiovascular disorders in hidradenitis suppurativa patients: a large-scale, propensity-matched global retrospective cohort study.
Krajewski PK; Matusiak Ł; Ständer S; Thaçi D; Szepietowski JC; Zirpel H
Int J Dermatol; 2024 Jun; 63(6):799-805. PubMed ID: 38644522
[TBL] [Abstract][Full Text] [Related]
19. The clinical, biochemical, and ultrasonographic characteristics of patients with hidradenitis suppurativa in Northern Peninsular Malaysia: a multicenter study.
Loo CH; Tan WC; Tang JJ; Khor YH; Manikam MT; Low DE; Chan KH; Chan KH; Teoh YM; Sohot NQA; Tang MM; Chan LC
Int J Dermatol; 2018 Dec; 57(12):1454-1463. PubMed ID: 30182482
[TBL] [Abstract][Full Text] [Related]
20. Demographic and clinical features of hidradenitis suppurativa in Korea.
Yang JH; Moon J; Kye YC; Kim KJ; Kim MN; Ro YS; Park MY; Ahn HH; Lee MW; Lee WJ; Lee JH; Lee JB; Jang MS; Choi YS; Choi YW; Suh DH;
J Dermatol; 2018 Dec; 45(12):1389-1395. PubMed ID: 30294846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
